Proteomics International Laboratories Ltd operates as a medical technology company with a focus on the area of proteomics in Australia, New Zealand, the United States, Europe, India, and South East Asia. It provides PromarkerD, a protein-based diagnostic blood test to predict diabetic kidney disease (DKD). The company's products under development include PromarkerEndo, which has completed clinical validation phase for endometriosis diagnosis; PromarkerEso, that has completed clinical validation trials for esophageal cancer diagnosis; and OxiDx (2-tag), which has completed clinical validation phase for oxidative stress treatment. It is also developing diagnostic tests for that includes DKD - T1D, that is under clinical phase for diabetic kidney disease in type 1 diabetes; Asthma and COPD, which has completed proof-of-concept study trials for asthma and chronic obstructive pulmonary disease; Plant Dieback, that is under development phase for phytophthora dieback; Diabetic Retinopathy, which has completed discovery phase for sight-threatening retinopathy; Diabetic Neuropathy, that is under research phase to investigate predictive biomarkers for diabetic neuropathy; and Giardia, a causing gastroenteritis. The company also offers analytical services, such as pharmacokinetic testing, biomarker discovery, protein analysis, project consultation, and specialist contract research. Proteomics International Laboratories Ltd was founded in 2001 and is headquartered in Perth, Australia.

Expand Company Description